Stimulated Whole Blood Cytokine Release as a Biomarker of Immunosuppression in the Critically Ill: The Need for a Standardized Methodology

Objective: Reduced ex vivo lipopolysaccharide (LPS) stimulated whole blood pro-inflammatory cytokine release is a hallmark of immunosuppression in the critically ill and predicts adverse clinical outcomes. No standard technique for performing the assay currently exists. The impact of methodological heterogeneity was determined. Design, Setting, Subjects, and Interventions: Clinical experimental study set in a research laboratory. Venous blood from 5 to 10 healthy volunteers/experiment (total participant group: 18 subjects, 72% men, mean age 32) was stimulated ex vivo to evaluate the effect of variables identified via literature review on tumor necrosis factor-&agr; (TNF&agr;) release. These included sample handling, stimulation technique, and incubation conditions. Reporting convention was additionally assessed. Main Results: Measured TNF&agr; release was significantly altered by source of LPS, concentration of LPS employed, duration and temperature of incubation prior to supernatant aspiration, and predilution of blood (repeated measures ANOVA, all P < 0.01). Sample handling prior to stimulation (anticoagulant employed, time to LPS addition, and storage temperature) also caused significant alterations in TNF&agr; release. Considerable interindividual variation was observed (range 1,024–4,649 pg/mL, mean 2,339 pg/mL). Normalization by monocyte count and pretreatment with a cyclooxygenase inhibitor (indomethacin 10 &mgr;M) reduced the coefficient of variation from 47.17% to 32.09%. Conclusions: Inconsistency in interlaboratory methodology and reporting impairs interpretation, comparability, and reproducibility of the ex vivo LPS-stimulated whole blood cytokine release assay. A standardized validated technique is required. The advent of trials of immunoadjuvant agents renders this a clinical imperative.

[1]  P. Pickkers,et al.  Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. , 2015, Minerva anestesiologica.

[2]  R. Hotchkiss,et al.  The new normal: immunomodulatory agents against sepsis immune suppression. , 2014, Trends in molecular medicine.

[3]  M. Netea,et al.  Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? , 2013, American journal of respiratory and critical care medicine.

[4]  J. Timsit,et al.  Inter‐laboratory assessment of flow cytometric monocyte HLA‐DR expression in clinical samples , 2013, Cytometry. Part B, Clinical cytometry.

[5]  R. Hotchkiss,et al.  Immunosuppression in patients who die of sepsis and multiple organ failure. , 2011, JAMA.

[6]  M. Netea,et al.  Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia* , 2011, Critical care medicine.

[7]  M. Bauer,et al.  The late phase of sepsis is characterized by an increased microbiological burden and death rate , 2011, Critical care.

[8]  J. Carcillo,et al.  Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome , 2011, Intensive Care Medicine.

[9]  N. Voirin,et al.  Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock , 2010, Intensive Care Medicine.

[10]  T. Baumann,et al.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. , 2009, American journal of respiratory and critical care medicine.

[11]  E. Mazzon,et al.  GREEN TEA POLYPHENOL EXTRACT ATTENUATES ZYMOSAN-INDUCED NON-SEPTIC SHOCK IN MICE , 2006, Shock.

[12]  N. Klein,et al.  Interleukin-10 and its role in clinical immunoparalysis following pediatric cardiac surgery* , 2006, Critical care medicine.

[13]  N. Voirin,et al.  Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock , 2006, Intensive Care Medicine.

[14]  E. Roth,et al.  Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. , 2006, Shock.

[15]  A. Nierhaus,et al.  Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis , 2003, Intensive Care Medicine.

[16]  M. West,et al.  Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. , 2003, Surgical infections.

[17]  J. Vincent,et al.  Response of tumour necrosis factor-alpha to delayed in vitro monocyte stimulation in patients with septic shock is related to outcome. , 2002, Clinical science.

[18]  A. Shigematsu,et al.  Role of interleukin-10 on hyporesponsiveness of endotoxin during surgery , 2000, Critical care medicine.

[19]  A. Aasen,et al.  Cytokine Modulation in Experimental Endotoxemia: Characterization of an ex vivo Whole Blood Model , 2000, European Surgical Research.

[20]  K. Asadullah,et al.  Diminished monocytic HLA-DR expression and ex vivo cytokine secretion capacity in patients with glioblastoma: Effect of tumor extirpation , 1998, Journal of Neuroimmunology.

[21]  K. Asadullah,et al.  Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. , 1997, Nature medicine.

[22]  F. Schildberg,et al.  Downregulation of proinflammatory cytokine release in whole blood from septic patients. , 1995, Blood.